IDEAYA BIOSCIENCES INC

Company Overview

IDEAYA Biosciences is a clinical-stage oncology-focused biotechnology company developing targeted medicines and synthetic lethal approaches, with lead programs that include darovasertib (entering a Phase 3 neoadjuvant trial, OptimUM-10, in Q3 2025) and pipeline assets IDE397, IDE161 and IDE849 plus several preclinical IND candidates planned in 2025. The company is collaboration-linked (notably a GSK agreement), has limited recurring revenue today (future receipts are expected to be milestone- or royalty-driven and therefore lumpy) and is materially R&D‑intensive — R&D costs rose 49% year‑over‑year and operating cash use accelerated. IDEAYA held ~$992M in cash and marketable securities at 6/30/2025 and expects at least a 12‑month runway but indicates substantial additional capital will be needed over time. The business model centers on advancing clinical milestones and partnering/licensing decisions as primary value inflection points.

Executive Compensation Practices

Given IDEAYA’s stage and the filing commentary, executive pay is likely skewed toward equity-heavy packages (stock options/RSUs and milestone- or performance‑based awards) to conserve cash while aligning management to clinical and partnering milestones such as trial starts, data readouts, INDs and collaboration payments. Management explicitly attributes part of recent expense growth to hiring and stock‑based compensation, indicating active use of equity to recruit and retain scientific and development talent as programs scale. Annual incentive metrics and long‑term incentives in this biotech context typically emphasize achievement of regulatory/clinical milestones, enrollment and data timelines, and business‑development outcomes (e.g., licensing or milestone payments from partners). Because G&A also rose from patent/legal and business‑development activity, some awards may be tied to protection and monetization of IP or successful partnership transactions.

Insider Trading Considerations

Insiders at IDEAYA will frequently possess material nonpublic information tied to trial initiations, enrollment progress, IND filings and clinical data readouts (e.g., darovasertib Phase 3 start and upcoming readouts), so standard blackout windows and pre‑planned Rule 10b5‑1 programs are common and advisable to avoid potential violations. Watch for Form 4 activity around periods when the company signals capital needs or executes financings — the company used an ATM program in the quarter and has stated it may pursue equity, which can coincide with insider option exercises or sales to cover tax liabilities and may be interpreted by market participants as liquidity-driven rather than fundamental. Because revenue is milestone‑driven and timing is lumpy, insiders with access to near‑term milestones have high informational sensitivity; market observers should scrutinize the timing of insider trades relative to clinical/partnering announcements and SEC Section 16/10b reporting windows.